SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-027550
Filing Date
2021-05-13
Accepted
2021-05-13 16:11:36
Documents
58
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-10q_20210331.htm 10-Q 1784047
2 EX-31.1 trvi-ex311_8.htm EX-31.1 14039
3 EX-32.1 trvi-ex321_6.htm EX-32.1 10381
  Complete submission text file 0001564590-21-027550.txt   5667327

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT trvi-20210331.xml EX-101.INS 1067011
5 XBRL TAXONOMY EXTENSION SCHEMA trvi-20210331.xsd EX-101.SCH 45187
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE trvi-20210331_cal.xml EX-101.CAL 39835
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE trvi-20210331_def.xml EX-101.DEF 127983
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20210331_lab.xml EX-101.LAB 340190
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20210331_pre.xml EX-101.PRE 258871
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 21919742
SIC: 2834 Pharmaceutical Preparations